Naslov
Hair loss and other adverse reactions during omalizumab treatment of chronic spontaneous urticaria- experience from the Clinical Hospital Center Rijeka

Autori
Knežević, Sandra ; Dujmović-Hasanbegović, Katarina ; Peternel, Sandra

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
2nd Symposium of the International Contact Dermatitis Research Group - abstract book / - , 2023

Skup
2nd Symposium of the International Contact Dermatitis Research Group

Mjesto i datum
Split, Hrvatska, 31.03.2023. - 02.04.2023

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Omalizumab ; Urticaria ; Alopecia

Sažetak
Introduction: Omalizumab is an anti-IgE monoclonal antibody approved for the treatment of chronic spontaneous urticaria (CSU) refractory to H1-antihistamines. The goal: To present our experience with the use of omalizumab in the treatment of CSU having the emphasis on adverse reactions. Material and methods: Treatment outcomes of CSU patients treated with omalizumab (300 mg s.c./month) for at least 6 months in the period from February 1st 2019 until January 31st 2023 at the Clinical Hospital Center Rijeka were observed retrospectively. Results: A total of 27 patients received at least a single dose of omalizumab and a total of 24 patients completed at least one 6-month cycle of therapy, of whom 22 achieved complete remission (CR) of the disease. A total of 249 doses were administered. 70% of our patients were women ; the median age was 53 years (range 18-75). During the observed period, 2 patients (7, 4%) discontinued omalizumab for treatment-related adverse reactions. A 70-year-old female patient with a previous history of alopecia areata (AA) experienced a severe relapse with almost total loss of scalp hair after the 3rddose of omalizumab. The treatment was permanently discontinued, which resulted in spontaneous and complete hair regrowth and no further relapse of AA throughout a 10-month follow-up. Interestingly, the patient also achieved CR of CSU during follow-up. Omalizumab was also discontinued in a 30-year-old female patient who experienced several adverse reactions including chronic telogen effluvium and debilitating polyarthralgia, whilst the disease was in CR during the 3rd 6-month cycle of therapy. Her joint symptoms completely resolved upon omalizumab cessation. Another female patient (66 years old) experienced only transient telogen effluvium and mild swelling of small joints after the 2nd dose of omalizumab, whilst achieving CR. Injection site reaction was reported by one patient. One patient developed hypertensive crisis during the administration of the 2nd dose of the 5th cycle, which was successfully managed. Conclusion: We wanted to report hair loss and polyarthralgia as a novelty in our clinical experience with the use of omalizumab. Although these are listed among omalizumab adverse reactions, there is no available data to estimate their frequency. Further clinical observation is needed.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA